Pfizer is set to release its fourth-quarter and full-year 2025 results on February 3 before the market opens. According to the Zacks Consensus, fourth-quarter revenues are forecast at $16.93 billion, while adjusted earnings per share are expected to reach $0.57. Investors will be watching sales trends in key franchises such as vaccines and oncology, as well as margin expansion driven by cost‐savings initiatives launched in early 2025.

The company faces patent expirations for major blockbusters Xeljanz and Ibrance between 2026 and 2028, which analysts warn could lead to a revenue decline of up to 15% in those franchises. Generic competition is already underway in certain markets, and Pfizer has projected that lost exclusivity could shave approximately $3 billion off annual top-line starting in 2026 unless mitigated by new launches.

Management highlights a diversified pipeline with recent FDA approvals in oncology and vaccines, including a novel pneumococcal vaccine expected to drive mid-teens percentage growth by 2027. Late-stage candidates MET-097i and MET-233i, both GLP-1/amylin dual agonists, are on track for Phase III readouts in H2 2026 and could represent a $5 billion annual opportunity at peak sales.

With a dividend yield above 3.5% and a 16-year streak of annual payouts, Pfizer remains a favored pick for income-oriented investors. However, some strategists caution that the risk–reward profile has shifted, arguing that pipeline upside may already be priced in and that quantified downside from upcoming patent cliffs warrants a more cautious allocation.